Evidence map›Paper›PMID 37530544›Full record

ArticleHepatology (Baltimore, Md.)2024

Predicting futility of upfront surgery in perihilar cholangiocarcinoma: Machine learning analytics model to optimize treatment allocation.

Francesca Ratti, Rebecca Marino, Pim B Olthof, Johann Pratschke, Joris I Erdmann, Ulf P Neumann, Raj Prasad, William R Jarnagin, Andreas A Schnitzbauer, Matteo Cescon and 21 more

Abstract read
PubMed Publisher
In one paragraph

Article in Hepatology (Baltimore, Md.), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed.

  1. The Role of Gut Microbiota in Liver Regeneration After Partial Hepatectomy: New Evidence From Animal and Human Studies.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2026
    Review
  2. Review
  3. Article
  4. Futility in adenosquamous pancreatic cancer.World journal of surgical oncology · 2026
    Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Present and future of liver transplantation for cholangiocellular carcinoma: moving toward personalized multiparametric transplantability patterns.Transplant international : official journal of the European Society for Organ Transplantation · 2026
    Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

31 authors.

Francesca RattiHepatobiliary Surgery Division, IRCCS Ospedale San Raffaele, Via Olgettina 60, Milano, Italy.
Rebecca MarinoHepatobiliary Surgery Division, IRCCS Ospedale San Raffaele, Via Olgettina 60, Milano, Italy.
Pim B OlthofDepartment of Surgery, Division of HPB and Transplant Surgery, Erasmus MC University Medical Center, Rotterdam, The Netherlands.
Johann PratschkeDepartment of Surgery, Charité-Universitätsmedizin, Berlin, Germany.
Joris I ErdmannDepartment of Surgery, Cancer Center Amsterdam, Amsterdam UMC, University of Amsterdam, The Netherlands.
Ulf P NeumannDepartment of General, Gastrointestinal, Hepatobiliary and Transplant Surgery, RWTH Aachen University Hospital, Aachen, Germany.
Raj PrasadDepartment of Hepatobiliary and Liver Transplant Surgery, Division of Surgery, St James's University Hospital, Leeds, United Kingdom.
William R JarnaginHepatopancreatobiliary Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
Andreas A SchnitzbauerDepartment of General and Visceral Surgery, University Hospital, Goethe University, Frankfurt, Germany.
Matteo CesconDepartment of General Surgery and Transplantation, IRCCS, Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy.
Alfredo GuglielmiUnit of General and Hepatobiliary Surgery, Department of Surgical Sciences, Dentistry, Gynecology and Pediatrics, University of Verona, Verona, Italy.
Hauke LangDepartment of General, Visceral and Transplant Surgery, University Hospital Mainz, Mainz, Germany.
Silvio NadalinDepartment of General and Transplant Surgery, University Hospital Tübingen, Tübingen, Germany.
Baki TopalDepartment of Abdominal Surgery, University Hospitals Gasthuisberg Leuven and KU Leuven, Leuven, Belgium.
Shishir K MaithelDivision of Surgical Oncology, Department of Surgery, Winship Cancer Institute, Emory University, Atlanta, GA.
Frederik J H HoogwaterDepartment of Surgery, Section of Hepatobiliary Surgery & Liver Transplantation, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands.
Ruslan AlikhanovDepartment of Liver and Pancreatic Surgery, Moscow Clinical Scientific Center, Russia.
Roberto TroisiDepartment of Clinical Medicine and Surgery, Division of Hepato-Bilio-Pancreatic, Minimally Invasive and Robotic Surgery, Federico II University Hospital, Naples, Italy.
Ernesto SparrelidDepartment of Clinical Science, Intervention and Technology (CLINTEC), Division of Surgery, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden.
Keith J RobertsDepartment of Surgery, University Hospital Birmingham, Birmingham, United Kingdom.
Massimo MalagòDepartment of HPB- and Liver Transplantation Surgery, University College London, Royal Free Hospitals, London, United Kingdom.
Jeroen HagendoornDepartment of Surgery, Regional Academic Cancer Centre Utrecht, St Antonius Hospital, Nieuwegein and University Medical Centre Utrecht, Utrecht, The Netherlands.
Hassan Z MalikDepartment of Hepatobiliary Surgery, Aintree University Hospital, Liverpool University Hospitals, NHS Foundation Trust, Liverpool, United Kingdom.
Steven W M Olde DaminkDepartment of General, Gastrointestinal, Hepatobiliary and Transplant Surgery, RWTH Aachen University Hospital, Aachen, Germany.
Geert KazemierDepartment of Surgery, Cancer Center Amsterdam, Amsterdam UMC, VU University, Amsterdam, The Netherlands.
Erik SchaddeDepartment of Surgery, Cantonal Hospital Winterthur, Zurich, Switzerland.
Ramon CharcoDepartment of HBP Surgery and Transplantation, Hospital Universitario Vall d'Hebron, Universidad Autónoma de Barcelona, Spain.
Philip R de ReuverDepartment of Surgery, Radboud University Medical Center, Nijmegen, the Netherlands.
Bas Groot KoerkampDepartment of Surgery, Division of HPB and Transplant Surgery, Erasmus MC University Medical Center, Rotterdam, The Netherlands.
Luca AldrighettiHepatobiliary Surgery Division, IRCCS Ospedale San Raffaele, Via Olgettina 60, Milano, Italy.
Perihilar Cholangiocarcinoma Collaboration Group

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundWhile resection remains the only curative option for perihilar cholangiocarcinoma, it is well known that such surgery is associated with a high risk of morbidity and mortality. Nevertheless, beyond facing life-threatening complications, patients may also develop early disease recurrence, defining a "futile" outcome in perihilar cholangiocarcinoma surgery. The aim of this study is to predict the high-risk category (futile group) where surgical benefits are reversed and alternative treatments may be considered.

methodsThe study cohort included prospectively maintained data from 27 Western tertiary referral centers: the population was divided into a development and a validation cohort. The Framingham Heart Study methodology was used to develop a preoperative scoring system predicting the "futile" outcome.

resultsA total of 2271 cases were analyzed: among them, 309 were classified within the "futile group" (13.6%). American Society of Anesthesiology (ASA) score ≥ 3 (OR 1.60; p = 0.005), bilirubin at diagnosis ≥50 mmol/L (OR 1.50; p = 0.025), Ca 19-9 ≥ 100 U/mL (OR 1.73; p = 0.013), preoperative cholangitis (OR 1.75; p = 0.002), portal vein involvement (OR 1.61; p = 0.020), tumor diameter ≥3 cm (OR 1.76; p < 0.001), and left-sided resection (OR 2.00; p < 0.001) were identified as independent predictors of futility. The point system developed, defined three (ie, low, intermediate, and high) risk classes, which showed good accuracy (AUC 0.755) when tested on the validation cohort.

conclusionsThe possibility to accurately estimate, through a point system, the risk of severe postoperative morbidity and early recurrence, could be helpful in defining the best management strategy (surgery vs. nonsurgical treatments) according to preoperative features.

Indexed as

Bile Duct NeoplasmsCholangiocarcinomaCholangitisKlatskin TumorHepatectomyHumansMedical FutilityNeoplasm Recurrence, LocalRetrospective StudiesTreatment Outcome

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.